Table 1. Patient characteristics of COVID-19 patients with thrombosis.
| Characteristics |
Thrombosis
n
= 138
n (%) |
|---|---|
| Age (y) Mean (range) |
59.6 (23–89) |
| Young <45 | 18 (13.0) |
| Middle aged (45–65) | 78 (56.5) |
| Elderly >65 | 42 (30.4) |
| Sex | |
| Male | 82 (59.4) |
| Female | 56 (40.5) |
| Race and ethnicity | |
| White | 15 (10.9) |
| African American | 56 (40.5) |
| Hispanic | 51 (36.8) |
| Other | 16 (11.6) |
| BMI (kg/m 2 ) | |
| Normal (<24.9) | 36 (26.1) |
| Overweight (25–29.9) | 41 (29.7) |
| Obese (>30) | 56 (40.5) |
| Unknown | 5 (3.6) |
| Thromboembolism type a | |
| Deep vein thrombosis | 71 (51.4) |
| Pulmonary embolism | 61 (44.2) |
| Stroke | 26 (18.8) |
| Anticoagulation prior to thrombosis | |
| None | 30 (21.7) |
| Prophylactic | 66 (47.8) |
| Enoxaparin | 43 (31.2) |
| Heparin | 23 (16.7) |
| Therapeutic | 41 (29.7) |
| Enoxaparin | 29 (21.0) |
| Heparin | 5 (3.6) |
| Apixaban | 4 (2.9) |
| Bivalirudin | 3 (2.2) |
| Unknown | 1 (0.7) |
| COVID-19-related therapy b | |
| Steroids | 64 (46.4) |
| Tocilizumab | 36 (26.1) |
| Remdesivir | 18 (13.0) |
| Hydrocychloroquine | 48 (34.8) |
| Mortality | 44 (31.9) |
| Hospital characteristics | |
| Length of stay Mean (range) |
20.5 (1–92) |
| ICU admission | 116 (84.1) |
| ICU length of stay Mean (range) |
18.7 (0.08–91.2) |
| Mechanical ventilation | 98 (71) |
| D-dimer > 6 | 68 (49.2) |
| Renal replacement therapy | 45 (32.6) |
Abbreviations: BMI, body mass index; COVID-19, novel coronavirus disease 2019; ICU, intensive care unit;
a
Some patients had multiple types of thromboembolism.
b
Some patients received multiple types of COVID-19 therapy.